Targeted Apolipoprotein Lipid Nanoparticles for Precise Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many therapeutics face challenges in reaching the intended target site effectively and often trigger unwanted immune responses, leading to degradation or inflammatory reactions.
Innovation Solution
Modified apolipoproteins are attached to a targeting body capable of binding to cell surface molecules, incorporated into lipid nanoparticles, allowing targeted delivery to specific cells, tissues, or organs while reducing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If therapeutics are delivered without targeting bodies, then the delivery system is simple, but the therapeutics cannot reach the intended target site effectively
Solution Approach 1:
The patent uses apolipoproteins as intermediary carriers that naturally interact with cell membranes and transport systems. These apolipoproteins serve as mediators between the therapeutic payload and the target cell, leveraging their biological compatibility to facilitate delivery without requiring complex targeting mechanisms. The apolipoprotein binds to the therapeutic agent and delivers it to the target site through natural cellular processes.
Solution Approach 2:
The patent employs apolipoproteins that can perform multiple functions: they serve as structural components of lipoparticles, facilitate cellular uptake through receptor interaction, and can be modified with targeting bodies to recognize specific cell surface molecules. This multi-functionality allows a single carrier system to achieve both delivery and targeting capabilities.
2Object-affected harmful factors
If therapeutics are delivered without targeting bodies, then the immune response is reduced, but off-target effects increase
Solution Approach 1:
The patent applies targeting bodies (such as antibodies or ligands) specifically to the apolipoprotein portion that will interact with target cell surface molecules. This localized modification ensures that the targeting functionality is concentrated at the interaction interface, improving specificity without requiring the entire apolipoprotein structure to be modified, thus minimizing unnecessary immune activation.
Solution Approach 2:
The apolipoprotein acts as a protective intermediary that shields the therapeutic payload from direct immune recognition while the targeting body on its surface mediates specific cell interaction. This separation of functions allows the carrier to deliver therapeutics to specific targets while minimizing broad immune activation.
3Measurement precision
If apolipoproteins are modified with targeting bodies, then targeted delivery is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent divides the apolipoprotein into functional segments: a core apolipoprotein structure that maintains its natural biological functions and stability, and a separate targeting body component that can be independently designed and attached. This segmentation allows each component to be optimized and manufactured separately before being combined, simplifying the overall manufacturing process.
Solution Approach 2:
The patent uses chemical conjugation techniques with intermediary linkers to attach targeting bodies to apolipoproteins. These linkers serve as manageable intermediaries that facilitate stable attachment while maintaining the functional integrity of both the apolipoprotein and targeting body, making the conjugation process controllable and reproducible for manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances targeted delivery of therapeutic agents to intended sites, minimizing immune responses and improving therapeutic efficacy.
Implementation Method 1
the targeting body is a molecule capable of binding a molecule on the cell surface of a target cell
Implementation Method 2
lipid nanoparticles comprising an outer layer and a core, wherein the outer layer comprises: a phospholipid; a sterol; and the modified apolipoprotein
Data Source
AI summary
The invention relates to modified apolipoprotein with a targeting body. The targeting body may for example be an antibody or antigen binding fragment that allows targeting of e.g. a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload as such or when incorporated in a lipid nanoparticle. The modified apolipoprotein finds use in the treatment or prevention of diseases, or targeting a pay load to a specific target site.